Last quarter (Q3 2024), Acasti Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Acasti Pharma's net income was $-2.39M. See Acasti Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	-	-	-	$ 196.00K	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	$ 76.00K	$ 0.00	-
Gross Profit	-	-	-	$ 120.00K	$ 0.00	-
Operating Expense	$ 13.56M	$ 18.25M	$ 15.34M	$ 10.84M	$ 24.44M	$ 33.66M
Operating Income	$ -13.56M	$ -18.25M	$ -15.34M	$ -10.72M	$ -24.44M	$ -33.66M
Net Non Operating Interest Income Expense	$ 773.00K	$ 246.00K	$ 224.00K	$ -107.00K	$ 43.00K	$ -427.00K
Other Income Expense	$ 35.80M	$ 33.90M	$ -4.95M	$ 2.69M	$ -1.12M	$ -5.27M
Pretax Income	$ -48.59M	$ -51.97M	$ -9.87M	$ -19.89M	$ -25.51M	$ -39.37M
Tax Provision	$ -9.81M	$ -9.54M	$ -648.00K	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -38.77M	$ -42.43M	$ -9.22M	$ -19.89M	$ -25.51M	$ -39.37M
Basic EPS	$ -1.83	-	$ -0.27	$ -10.64K	$ -2.40	$ -0.73
Diluted EPS	$ -1.83	-	$ -0.27	$ -10.64K	$ -2.40	$ -0.73
Basic Average Shares	$ 71.45M	-	$ 36.84M	$ 1.85B	$ 10.57M	$ 54.29M
Diluted Average Shares	$ 71.45M	-	$ 36.84M	$ 1.85B	$ 10.57M	$ 54.29M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.52M	-	$ 15.34M	$ -10.91M	$ 24.44M	$ 33.66M
Net Income From Continuing And Discontinued Operation	$ -38.77M	$ -42.43M	$ -9.22M	$ -19.89M	$ -25.51M	$ -39.37M
Normalized Income	$ -24.49M	$ -27.61M	$ -10.27M	$ -8.65M	$ -24.39M	$ -34.09M
Interest Expense	-	-	-	-	$ 247.00K	$ 278.00K
EBIT	$ -48.59M	$ -51.97M	$ -9.87M	$ -19.89M	$ -25.27M	$ -39.09M
EBITDA	$ -48.57M	$ -51.85M	$ -9.87M	$ -18.97M	$ -22.95M	$ -36.76M

Currency in USD

Acasti Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing